ERCC1 and non-small cell lung carcinoma: Olaussen et al. [18] reported that negative ERCC1 expression, determined by IHC using the 8F1 antibody, was associated with better survival in operated NSCLC patients treated with adjuvant platinum-based chemotherapy.